Osteoarthritis Pain ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Osteoarthritis Pain ' Pipeline Review, H2 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's, 'Osteoarthritis Pain - Pipeline Review, H2 2012', provides an overview of the Osteoarthritis Pain therapeutic
pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Osteoarthritis Pain. 'Osteoarthritis Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets
Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Osteoarthritis Pain.
- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development
progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Osteoarthritis Pain
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Osteoarthritis Pain ' Pipeline Review, H2 2012 (From Slideshare) Page 1/10


Table of Content

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoarthritis Pain Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Osteoarthritis Pain 11
Osteoarthritis Pain Therapeutics under Development by Companies 13
Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Early Clinical Stage Products 19
Discovery and Pre-Clinical Stage Products 20
Osteoarthritis Pain Therapeutics ' Products under Development by Companies 21
Osteoarthritis Pain Therapeutics ' Products under Investigation by Universities/Institutes 24
Companies Involved in Osteoarthritis Pain Therapeutics Development 25
Genzyme Corporation 25
Johnson & Johnson 26
Abbott Laboratories 27
Allergan, Inc. 28
Sanofi-Aventis 29
Eli Lilly and Company 30
BioDelivery Sciences International, Inc. 31
Nektar Therapeutics 32
MedImmune LLC 33
Cephalon, Inc. 34
Menarini Group 35
BioChemics, Inc. 36
Addex Pharmaceuticals 37
Elite Pharmaceuticals, Inc. 38
WhanIn Pharmaceutical Co., Ltd. 39
Array BioPharma Inc. 40
AnaMar Medical AB 41
Neurotune AG 42
IDEA AG 43
QRxPharma Limited 44
Iroko Pharmaceuticals, LLC 45
Winston Pharmaceuticals, Inc. 46



SantoSolve AS 47
Antibe Therapeutics, Inc. 48
Flexion Therapeutics 49
Afferent Pharmaceuticals, Inc. 50
Apimeds, Inc. 51
Osteoarthritis Pain ' Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
CEP-33237 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ADX71943 - Drug Profile 59
R&D Progress 59
NT-11624 - Drug Profile 60
R&D Progress 60
ELI-216 - Drug Profile 62
R&D Progress 62
Vicodin CR - Drug Profile 64
R&D Progress 64
Nucynta - Drug Profile 66
R&D Progress 66
ABT-110 - Drug Profile 69
R&D Progress 69
ARRY-797 - Drug Profile 70
R&D Progress 70
BEMA Buprenorphine - Drug Profile 72
R&D Progress 72
Diractin - Drug Profile 74



R&D Progress 74
IP 045 - Drug Profile 76
R&D Progress 76
MoxDuo CR - Drug Profile 77
R&D Progress 77
TASS - Drug Profile 79
R&D Progress 79
GRT6005 - Drug Profile 80
R&D Progress 80
AF-219 - Drug Profile 81
R&D Progress 81
JNJ-39439335 - Drug Profile 82
R&D Progress 82
Gen-S - Drug Profile 83
R&D Progress 83
Apitoxin - Drug Profile 84
R&D Progress 84
Intra-Articular Civamide - Drug Profile 85
R&D Progress 85
Botox - Drug Profile 86
R&D Progress 86
NKTR-181 - Drug Profile 88
R&D Progress 88
Botox - Drug Profile 90



R&D Progress 90
SAR-292833 - Drug Profile 92
R&D Progress 92
ABT-652 - Drug Profile 94
R&D Progress 94
2PX - Drug Profile 95
R&D Progress 95
Fasitibant - Drug Profile 97
R&D Progress 97
MEDI-578 - Drug Profile 99
R&D Progress 99
Carbamazepine - Drug Profile 100
R&D Progress 100
FX005 - Drug Profile 101
R&D Progress 101
GABA-BR PAM - Drug Profile 102
R&D Progress 102
THA902 - Drug Profile 103
R&D Progress 103
R&D Progress 104
R&D Progress 105
ibuprofen - Drug Profile 106



R&D Progress 106
ATB-346 - Drug Profile 107
R&D Progress 107
Drug For Osteoarthritis Pain - Drug Profile 108
R&D Progress 108
WIN-34B - Drug Profile 109
R&D Progress 109
Osteoarthritis Pain Therapeutics ' Drug Profile Updates 110
Osteoarthritis Pain Therapeutics ' Discontinued Products 123
Osteoarthritis Pain Therapeutics - Dormant Products 125
Osteoarthritis Pain ' Product Development Milestones 127
Featured News & Press Releases 127
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 127
May 30, 2012: Flexion's FX005 Demonstrates Significant Prolonged Improvement In Pain And Function In Phase II Trial 127
May 01, 2012: Endo Pharma Provides Supply Update On Voltaren Gel 128
Aug 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week
2010 128
Aug 30, 2010: J&JPRD And Grunenthal Report Phase III Study Data Comparing Tapentadol ER To Placebo In Patients With Chronic
Osteoarthritis Knee Pain 128
Aug 19, 2010: Lilly Reports Approval Recommendation From FDA Advisory Committee For Expanding Pain Indications For Cymbalta
129
Jun 19, 2010: SantoSolve AS Present 2PX at EULAR congress 130
Nov 17, 2009: SantoSolve Completes Patient Enrollment In First Pivotal Phase III Trial In Osteoarthritis 130
Mar 12, 2009: Glenmark's GRC 15300 To Enter Phase I Trials 131
Jan 24, 2009: Glenmark Pharma To Develop GRC 15300 131
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 133
Disclaimer 133

List of Tables

Number of Products Under Development for Osteoarthritis Pain, H2 2012 11
Products under Development for Osteoarthritis Pain ' Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16



Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Development by Companies, H2 2012 (Contd..1) 22
Products under Development by Companies, H2 2012 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2012 24
Genzyme Corporation, H2 2012 25
Johnson & Johnson, H2 2012 26
Abbott Laboratories, H2 2012 27
Allergan, Inc., H2 2012 28
Sanofi-Aventis, H2 2012 29
Eli Lilly and Company, H2 2012 30
BioDelivery Sciences International, Inc., H2 2012 31
Nektar Therapeutics, H2 2012 32
MedImmune LLC, H2 2012 33
Cephalon, Inc., H2 2012 34
Menarini Group, H2 2012 35
BioChemics, Inc., H2 2012 36
Addex Pharmaceuticals, H2 2012 37
Elite Pharmaceuticals, Inc., H2 2012 38
WhanIn Pharmaceutical Co., Ltd., H2 2012 39
Array BioPharma Inc., H2 2012 40
AnaMar Medical AB, H2 2012 41
Neurotune AG, H2 2012 42
IDEA AG, H2 2012 43
QRxPharma Limited, H2 2012 44
Iroko Pharmaceuticals, LLC, H2 2012 45
Winston Pharmaceuticals, Inc., H2 2012 46
SantoSolve AS, H2 2012 47
Antibe Therapeutics, Inc., H2 2012 48
Flexion Therapeutics, H2 2012 49
Afferent Pharmaceuticals, Inc., H2 2012 50
Apimeds, Inc., H2 2012 51
Assessment by Monotherapy Products, H2 2012 52
Assessment by Stage and Route of Administration, H2 2012 54
Assessment by Stage and Molecule Type, H2 2012 56
Osteoarthritis Pain Therapeutics ' Drug Profile Updates 110
Osteoarthritis Pain Therapeutics ' Discontinued Products 123
Osteoarthritis Pain Therapeutics ' Discontinued Products (Contd..1) 124
Osteoarthritis Pain Therapeutics ' Dormant Products 125
Osteoarthritis Pain Therapeutics ' Dormant Products (Contd..1) 126

List of Figures

Number of Products under Development for Osteoarthritis Pain, H2 2012 11
Products under Development for Osteoarthritis Pain ' Comparative Analysis, H2 2012 12



Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 52
Assessment by Route of Administration, H2 2012 53
Assessment by Stage and Route of Administration, H2 2012 54
Assessment by Molecule Type, H2 2012 55
Assessment by Stage and Molecule Type, H2 2012 56


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Osteoarthritis Pain ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Osteoarthritis Pain ' Pipeline Review, H2 2012